Risk Factors | n | Number Recovered Within 5 Years | Years Since Onset of Proteinuria | p | ||||
---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | ||||
Race | ||||||||
White | 123 | 75 | 30 | 55 | 62 | 70 | 76 | 0.68 |
Black | 36 | 21 | 19 | 52 | 73 | 80 | 80 | |
Asian | 31 | 15 | 31 | 44 | 55 | 66 | 66 | |
Other | 22 | 9 | 26 | 39 | 39 | 62 | 62 | |
Sex | ||||||||
Female | 178 | 103 | 28 | 54 | 63 | 71 | 76 | 0.31 |
Male | 34 | 17 | 27 | 39 | 54 | 64 | 64 | |
Age, yrs | ||||||||
< 30 | 101 | 58 | 26 | 50 | 61 | 71 | 77 | 0.89 |
30–50 | 84 | 49 | 25 | 52 | 62 | 69 | 72 | |
≥ 50 | 27 | 13 | 45 | 56 | 56 | 65 | 65 | |
Disease duration, yrs | ||||||||
< 5 | 122 | 71 | 32 | 54 | 63 | 74 | 79 | 0.12 |
≥ 5 yrs | 90 | 49 | 22 | 49 | 58 | 66 | 68 | |
DNA (Farr assay) | ||||||||
Normal | 66 | 42 | 31 | 64 | 70 | 75 | 79 | 0.20 |
Abnormal | 132 | 73 | 28 | 47 | 57 | 68 | 71 | |
Complement | ||||||||
Normal | 71 | 47 | 36 | 61 | 73 | 80 | 84 | 0.01 |
Low | 139 | 72 | 25 | 47 | 55 | 65 | 68 | |
Biopsy class | ||||||||
3 | 29 | 19 | 33 | 44 | 52 | 65 | 70 | |
4, or 4 and 5 | 68 | 39 | 27 | 51 | 61 | 71 | 74 | 0.36 |
5 | 24 | 18 | 36 | 73 | 73 | 83 | 83 | |
Proteinuria level | ||||||||
< 1 | 30 | 21 | 45 | 77 | 86 | 91 | 91 | |
1–2 | 74 | 41 | 38 | 55 | 64 | 72 | 72 | 0.003 |
≥ 2 | 108 | 58 | 17 | 43 | 52 | 63 | 70 | |
Steroids at start | ||||||||
No | 32 | 18 | 26 | 59 | 68 | 68 | 68 | 0.85 |
Yes | 108 | 102 | 28 | 50 | 60 | 71 | 75 | |
Antimalarial at start | ||||||||
No | 128 | 76 | 29 | 53 | 63 | 70 | 74 | 0.59 |
Yes | 84 | 44 | 27 | 50 | 58 | 70 | 74 | |
Immunosuppressants at start | ||||||||
No | 112 | 62 | 29 | 52 | 63 | 70 | 73 | 0.55 |
Yes | 100 | 58 | 27 | 51 | 58 | 71 | 75 | |
Steroids in 1 yr from start | ||||||||
No | 6 | 13 | 20 | 20 | 20 | 20 | 20 | 0.09 |
Yes | 206 | 119 | 28 | 52 | 62 | 71 | 75 | |
Antimalarial in 1 yr from start | ||||||||
No | 105 | 58 | 26 | 50 | 61 | 69 | 72 | 0.65 |
Yes | 107 | 62 | 30 | 53 | 62 | 72 | 77 | |
Immunosuppressants in 1 yr from start | ||||||||
No | 42 | 19 | 31 | 43 | 64 | 70 | 70 | 0.97 |
Yes | 170 | 101 | 27 | 53 | 61 | 70 | 75 | |
eGFR | ||||||||
≤ 60 ml/min/1.73 m2 | 67 | 36 | 29 | 53 | 70 | 73 | 80 | 0.37 |
> 60 | 145 | 84 | 28 | 51 | 58 | 69 | 72 | |
sCr | ||||||||
≤ 140 μmol/l | 178 | 99 | 29 | 51 | 59 | 69 | 72 | 0.31 |
> 140 μmol/l | 34 | 21 | 24 | 55 | 75 | 80 | 85 | |
SLEDAI-2K | ||||||||
≤ 10 | 37 | 21 | 34 | 57 | 65 | 65 | 65 | 0.85 |
> 10 | 175 | 99 | 27 | 50 | 60 | 71 | 77 | |
CRP | ||||||||
Normal | 27 | 17 | 35 | 61 | 66 | 66 | 72 | 0.92 |
Abnormal | 5 | 3 | 25 | 63 | 100 | 100 | 100 | |
HsCRP | ||||||||
Normal | 54 | 30 | 31 | 48 | 63 | 74 | 83 | 0.30 |
Abnormal | 27 | 18 | 28 | 72 | 72 | 86 | 86 | |
ESR | ||||||||
Normal | 45 | 27 | 31 | 50 | 62 | 72 | 72 | 0.86 |
Abnormal | 121 | 62 | 27 | 50 | 59 | 67 | 73 | |
Albumin | ||||||||
< 35 g/l | 121 | 69 | 25 | 51 | 59 | 69 | 76 | 0.65 |
≥ 35 g/l | 88 | 49 | 33 | 52 | 65 | 71 | 71 | |
Cholesterol | ||||||||
Normal | 69 | 38 | 34 | 50 | 60 | 73 | 76 | 0.72 |
Abnormal | 135 | 78 | 25 | 53 | 61 | 69 | 73 | |
Hypertensive* | ||||||||
No | 94 | 50 | 24 | 52 | 62 | 71 | 71 | 0.53 |
Yes | 117 | 70 | 31 | 51 | 60 | 70 | 76 |
↵* Hypertensive patients either had documented high blood pressure or were taking antihypertensive drugs. SLEDAI-2K: SLE Disease Activity Index-2000; eGFR: estimated glomerular filtration rate; ESR: erythrocyte sedimentation rate; HsCRP: high-sensitivity C-reactive protein; sCr: serum creatinine.